Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized,...

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis C virus (HCV) infection is a significant global health concern.
• Direct-acting antivirals (DAAs) have revolutionized HCV treatment.
• Setrobuvir is a novel non-nucleoside inhibitor targeting HCV polymerase.

Purpose of the Study:

• To evaluate the efficacy and safety of interferon-free regimens containing setrobuvir in HCV genotype 1 patients.
• To assess combinations of setrobuvir with danoprevir/r and ribavirin, with or without mericitabine.

Main Methods:

• A randomized study involving 110 non-cirrhotic, treatment-naïve patients with HCV genotype 1.
• Patients received either 2 or 3 DAAs plus ribavirin for 12 or 24 weeks, following a lead-in period.
• Sustained virological response at 12 weeks (SVR12) was the primary efficacy endpoint.

Main Results:

• Two treatment arms were discontinued due to futility.
• SVR12 rates varied by regimen and genotype, with some arms achieving over 95% response.
• All patients receiving 24 weeks of a 3-DAA regimen who showed significant viral load reduction during lead-in achieved SVR12.
• The regimens were generally well-tolerated with mild to moderate adverse events.

Conclusions:

• An interferon-free regimen combining setrobuvir, danoprevir/r, and ribavirin is safe and effective for treatment-naïve HCV genotype 1 patients.
• The study supports the development of setrobuvir-based interferon-free therapies for HCV.